


Image produced by Allison Woolford of Astex

SECOND
ANNOUNCEMENT
& CALL FOR ABSTRACTS

BURSARIES
AVAILABLE FOR
PhD/PostDocs



Fragments 2024

9th RSC-BMCS Fragment-based Drug Discovery Meeting

3rd – 5th March, 2024

Hinxton Hall, Cambridge, UK



Synopsis

The aim of the 9th RSC-BMCS Fragment-based Drug Discovery meeting will be to continue the focus on case studies in Fragment-based Drug Discovery that have delivered compounds to late stage medicinal chemistry, preclinical or clinical programmes. The Fragment series was started in 2007 and continues with this theme in having over three-quarters of the presentations focused on case studies. This will be complemented by technology progress in high concentration, NMR, SPR and X-ray screening.

Who should attend

This conference is suitable for scientists including chemists, biophysicists, structural biologists, etc., with either existing experience of fragments or wanting to learn about this exciting approach to drug discovery. This international meeting attracts delegates from the UK, several mainland European countries, as well as from the USA, Japan, China and South Korea.

Pre-Conference workshop

A pre-conference workshop is planned with some new material to offer those new to the area of FBLD, including an introduction into the fundamental principles governing fragment-based drug discovery approaches. A series of four short presentations with opportunities for discussions is planned. This will be for 2.5 hours on Sunday afternoon.

Confirmed speakers

Charlotte Deane, *University of Oxford, UK*

Justin Dietrich, *Abbvie, US*

Dan Erlanson, *Frontier Medicines, US*

Anna Hirsch, *Helmholtz Institute for
Pharmaceutical Research Saarland (HIPS),
Germany*

Iacovos Michaelides and Gavin Collie,
AstraZeneca, UK

Jonathan Pettinger, *GSK, UK*

Gerald Platzer, *University of Vienna, Austria*

David Rees, *Astex, UK*

John Spencer, *University of Sussex, UK*

Rob Van Monfort, *Institute of Cancer
Research, UK*

Nicola Wilsher, *Astex, UK*

Organising Committee



Emma Grant
GSK



Gordon Saxty
NS-MC Consulting LTD (Chair)



Mary Wheldon
University of Dundee (Treasurer)



Iva Lukac
Charnwood Molecular



Marianne Schimpl
AstraZeneca



Alison Woolford
Astex Pharmaceuticals

Secretariat contact:

Hg3 Conferences
events@hg3.co.uk
+44 (0) 1423 529333

To find out more, visit the BMCS website by using
the URL or by scanning the QR code here:

<https://www.rscbmcs.org/events/fragments24>



SCAN ME